U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • Gold

    1,788.10
    +1.20 (+0.07%)
     
  • Silver

    23.14
    -0.40 (-1.70%)
     
  • EUR/USD

    1.1322
    +0.0110 (+0.99%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3342
    +0.0022 (+0.16%)
     
  • USD/JPY

    113.2600
    -2.0790 (-1.80%)
     
  • BTC-USD

    54,161.82
    -317.41 (-0.58%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.66 (-2.53%)
     

Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen.

  • According to data released at the European Society for Medical Oncology 2021 (ESMO21), Libtayo, used on top of platinum doublet chemotherapy, reduced the risk of death by 29% over chemo alone in patients with previously untreated, advanced non-small cell lung cancer (NSCLC).

  • The phase 3 Empower-Lung 3 trial included both squamous and nonsquamous NSCLC patients.

  • Libtayo-chemo hit a median overall survival (OS) of 22 months versus 13 months for the solo chemo group, with a median progression-free survival of 8 months.

  • The Libtayo combo posted a 43% response rate compared with 23% for chemo and a 16-month duration response versus 7 months for chemo. No new Libtayo safety signals were identified.

  • Exploratory analyses showed survival improvements across squamous and nonsquamous histologies and in patients with reduced daily functioning.

  • In another exploratory analysis, the Libtayo combination helped delay patient-reported quality of life deterioration and pain symptoms.

  • Price Action: REGN stock closed 0.20% lower at $651.88, and SNY stock closed at 0.39% higher at $48.38 on Friday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.